RxDoctor Payments Data

Brandon Connerly, MD

Family Medicine · New Salisbury, INNPI 1558361899

Payments from drug & device makers

$865in general payments, 2019–2025

Across 51 payments — averaging $16.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$174
  • Novo Nordisk$155
  • Amgen$77
  • Lilly USA, LLC$71
  • Merck$70
  • AbbVie$60
  • plus $257 from 6 others

What the payments were for

  • Food & beverage$865100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca12$174
Novo Nordisk9$155
Amgen4$77
Lilly USA, LLC4$71
Merck5$70
AbbVie(2 entities)3$60
Pfizer4$57
GSK3$54
Exact Sciences2$50
Novartis2$45
Boehringer Ingelheim2$30
Johnson & Johnson1$20

How this compares

$865 in reported general payments places this provider in the 55th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$40,150
Medicare patients
151
Services billed
643

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol60$48,302
JanuviaSitagliptin Phosphate18$23,648
JardianceEmpagliflozin17$23,069
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$21,804
EliquisApixaban23$19,793
MounjaroTirzepatide17$18,025
LinzessLinaclotide12$17,844
OzempicSemaglutide16$15,705
RybelsusSemaglutide15$14,527
Tresiba Flextouch U-100Insulin Degludec25$12,088
Breo ElliptaFluticasone/Vilanterol15$9,486
LantusInsulin Glargine,hum.Rec.Anlog14$5,754
Albuterol Sulfate HfaAlbuterol Sulfate138$2,690
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen89$2,609
Niacin ErNiacin26$2,384

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$174$48,30260 claims
GSKTrelegy Ellipta, Breo Ellipta$54$31,29046 claims
Novo NordiskOzempic, Rybelsus$155$30,23231 claims
MerckJanuvia$70$23,64818 claims
Boehringer IngelheimJardiance$30$23,06917 claims
PfizerEliquis$57$19,79323 claims
AbbVieLinzess, Synthroid$60$19,04032 claims
Lilly USA, LLCMounjaro$71$18,02517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in New Salisbury

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →